Fig. 1.

Images of two patients in the study. a Patient 2, a high-risk patient with a Gleason 5+4 high-flow tumor and metastatic disease. To the left, ⁶⁸Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) with automatically drawn volumes of interest (VOIs) from standard uptake value (SUV) 6 fixed threshold in blue. The first ⁸²Rb PET/CT scan in the middle and the second scan to the right. b Patient 9, a low-risk patient in active surveillance with a low-flow tumor. To the left, t2-weighted magnetic resonance imaging with hand-drawn VOIs in light blue. The first ⁸²Rb PET/CT scan in the middle and the second scan to the right